Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
Article first published online: 24 JAN 2013
© 2012 Blackwell Publishing Ltd
Diabetes, Obesity and Metabolism
Volume 15, Issue 4, pages 372–382, April 2013
How to Cite
Stenlöf, K., Cefalu, W. T., Kim, K.-A., Alba, M., Usiskin, K., Tong, C., Canovatchel, W. and Meininger, G. (2013), Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity and Metabolism, 15: 372–382. doi: 10.1111/dom.12054
- Issue published online: 25 FEB 2013
- Article first published online: 24 JAN 2013
- Accepted manuscript online: 26 DEC 2012 01:25PM EST
- Manuscript Accepted: 15 DEC 2012
- Manuscript Revised: 22 NOV 2012
- Manuscript Received: 6 NOV 2012
- 12Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669–672., , et al.
- 13Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM) (Abstract 0999-P). Diabetes 2011; 60(Suppl. 1): A274., , et al.
- 14Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion (Abstract 79-OR). Diabetes 2012; 61(Suppl. 1): A22., , et al.
- 15Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes mellitus (T2DM) by a non-renal mechanism (Abstract 84-OR). Diabetes 2012; 61(Suppl. 1): A24., , et al.
- 16Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: 2067–2073., , et al.
- 18Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes (Abstract 646-P). Diabetes 2010; 59(Suppl. 1)., , ,